Medtronic gains key approval for new mapping and ablation system
Medtronic acquired the technology in a 2022 deal reportedly worth $925 million.
Related Articles
Cardiologists make history, perform first-ever transcaval TAVR for pure aortic regurgitation
The 65-year-old male patient presented with a long medical history and many comorbidities, making surgery too risky and transcaval access was the best path forward.
TAVR or SAVR? ChatGPT could help cardiologists decide
Researchers asked ChatGPT to make treatment decisions for patients with severe aortic stenosis, comparing its answers to the recommendations of a full heart team.
TAVR, SAVR both linked to low reintervention rates after five years
While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team’s full analysis is…
Sex, energy drinks and vaccines among the many topics planned for preventive cardiology conference
The three-day event will include sessions about sexual activity among heart patients, depression, energy drinks, stimulants, vaccines and more. The festivities begin Thursday, April 25,…
New ACC President Cathie Biga wants to improve quality reporting in cardiology
Biga, who originally trained as a nurse, specializes in the business side of cardiology. She also emphasized the increasing importance of AI and other new…
Cardiologist loses medical license for allegedly ‘fondling and groping’ multiple patients
“The alleged conduct of this physician is so egregious, only the permanent revocation of his license could adequately protect the public from the risks posed…
Cardiologists make history, perform first-ever transcaval TAVR for pure aortic regurgitation
The 65-year-old male patient presented with a long medical history and many comorbidities, making surgery too risky and transcaval access was the best path forward.
Motivation helps heart patients stay active
Alexander Fanaroff, MD, said the late-breaking BE ACTIVE clinical trial presented at ACC.24 offers a blueprint for how to get patients to be more physically…
FDA announces new recall of Abbott’s HeartMate LVADs after 14 deaths
The issue at the center of this recall, which includes both the HeartMate II and HeartMate 3 LVAD, is the gradual buildup of biological materials.…
Keto diet ‘does not fulfill the criteria of a healthy diet,’ could be harmful for heart patients
The popular high-fat, low-carb diet is associated with multiple short-term benefits, but they appear to diminish over time.